THCT · As filed with the SEC
THC Therapeutics cash flow statement, by quarter
The statement as THC Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENT OF CASH FLOWS · USD
| USD | Q4 FY24† 3 months ended Jul 31, 2024 | Q3 FY24† 3 months ended Apr 30, 2024 | Q2 FY24† 3 months ended Jan 31, 2024 | Q1 FY24 3 months ended Oct 31, 2023 | Q4 FY23† 3 months ended Jul 31, 2023 | Q3 FY23† 3 months ended Apr 30, 2023 | Q2 FY23† 3 months ended Jan 31, 2023 | Q1 FY23 3 months ended Oct 31, 2022 |
|---|---|---|---|---|---|---|---|---|
| Cash Flows from Operating Activities | ||||||||
| Net loss | (281,724)† | 104,622† | (571,975)† | (62,485) | (32,941)† | 94,355† | 1,685,852† | (2,134,302) |
| Adjustments to reconcile net loss to net cash used by operating activities: | ||||||||
| Loss (gain) on change in derivative liabilities | 173,060† | (502,657)† | 467,154† | (12,113) | (41,875)† | (171,604)† | (1,979,597)† | 2,008,933 |
| Interest Expense | — | — | 0† | 0 | 0† | 0† | 0† | 0 |
| Stock-Based Compensation Expense | 0† | 222,000† | 0† | 0 | 0† | 0† | 65,890† | 21,280 |
| Gain on settlement of debt | — | — | — | — | — | 0† | 0† | (2,310) |
| Gain on settlement of debt | 0† | 0† | 0† | 0 | 850† | 0† | 0† | — |
| Depreciation Expense | 351† | 344† | 351† | 351 | 351† | 340† | 351† | 351 |
| Changes in operating assets and liabilities | ||||||||
| Increase in inventory | 0† | 0† | 0† | 0 | 0† | 0† | (1,626)† | — |
| Decrease in prepaid assets | 0† | 0† | 0† | 970 | 0† | (39,137)† | 995† | 1,651 |
| Change in Other Working Capital | — | — | — | — | — | 524† | 40,132† | (970) |
| Increase in accounts payable and accrued expenses | 26,796† | 38,629† | 58,500† | 72,156 | 73,568† | 73,392† | 126,207† | 82,781 |
| Increase (decrease) in accounts payable related party | — | — | — | — | — | 815† | 1,069† | 1,101 |
| Change in Accounts Payable | 80,703† | 0† | 842† | 852 | 0† | 815† | 1,069† | — |
| Net cash used in operating activities | (814)† | (137,062)† | (45,128)† | (269) | (47)† | (2,178)† | (61,722)† | (21,485) |
| Net Cash from Investing Activities | — | — | 0† | 0 | 0† | 0† | 0† | 0 |
| Cash Flows provided by Financing Activities | ||||||||
| Proceeds from Debt Issuance | 0† | 85,480† | 236† | 269 | 42† | 0† | 2,509† | 33,451 |
| Payments on related party advances | 0† | 0† | (527)† | 0 | 0† | (6,642)† | (35,513)† | (8,437) |
| Proceeds from Investments | — | — | — | — | — | 0† | — | — |
| Stock Repurchases (Issuances) | 0† | 0† | — | — | 0† | 0† | — | — |
| Repurchase of common stock | — | — | — | — | 0† | 0† | — | — |
| Proceeds from Stock Issuance | 0† | 48,920† | — | — | 0† | 0† | — | — |
| Net cash provided by financing activities | 0† | 134,400† | 48,629† | 269 | 42† | (6,642)† | 66,996† | 25,014 |
| Net increase in Cash | — | — | 3,501† | 0 | — | (8,820)† | 5,274† | 3,529 |
| Net decrease in Cash | (814)† | — | — | — | (5)† | — | — | — |
| Beginning cash balance | 849 | 3,511 | 10 | 10 | 15 | 8,835 | 3,561 | 32 |
| Ending cash balance | 35 | 849 | 3,511 | 10 | 10 | 15 | 8,835 | 3,561 |
| Supplemental disclosure of cash flow information | ||||||||
| Interest Expense | 0† | 0† | 0† | 0 | 0† | 0† | 0† | 0 |
| Cash paid for tax | — | — | — | 0 | 0† | 0† | 0† | 0 |
| Silver used to settle debt | — | — | — | — | 0† | 0† | 0† | 152,785 |
| Income Tax Expense | 0† | — | — | — | 0† | — | — | — |
| SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
| Silver used to settle debt | 0† | 0† | — | — | 0† | 0† | — | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.